Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,076,322
  • Shares Outstanding, K 93,855
  • Annual Sales, $ 933,010 K
  • Annual Income, $ -703,490 K
  • 60-Month Beta 0.94
  • Price/Sales 9.65
  • Price/Cash Flow N/A
  • Price/Book 13.92
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 50.52% ( +3.60%)
  • Historical Volatility 42.14%
  • IV Percentile 30%
  • IV Rank 6.86%
  • IV High 247.47% on 10/20/23
  • IV Low 36.02% on 12/01/23
  • Put/Call Vol Ratio 0.35
  • Today's Volume 3,196
  • Volume Avg (30-Day) 3,050
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 79,988
  • Open Int (30-Day) 69,953

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 6
  • High Estimate 0.32
  • Low Estimate -0.62
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +92.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.42 +2.03%
on 02/05/24
143.00 -13.37%
on 02/16/24
+2.61 (+2.15%)
since 02/02/24
3-Month
83.97 +47.53%
on 12/05/23
143.00 -13.37%
on 02/16/24
+37.76 (+43.85%)
since 12/04/23
52-Week
55.25 +124.22%
on 10/31/23
159.89 -22.52%
on 05/15/23
-31.73 (-20.39%)
since 03/03/23

Most Recent Stories

More News
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

The upcoming regulatory decision on its latest drug could be big.

SRPT : 123.88 (-3.72%)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.

SRPT : 123.88 (-3.72%)
Sarepta Therapeutics: Q4 Earnings Snapshot

Sarepta Therapeutics: Q4 Earnings Snapshot

SRPT : 123.88 (-3.72%)
Is It Too Late to Buy Sarepta Therapeutics Stock?

The company's hyperfocus on its core area could continue to be highly lucrative.

SRPT : 123.88 (-3.72%)
Why Sarepta Therapeutics Stock Is Soaring Today

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

JPM : 186.68 (+0.75%)
SRPT : 123.88 (-3.72%)
2 Magnificent Growth Stocks to Buy With $500

No need to break the bank to invest in promising stocks.

SRPT : 123.88 (-3.72%)
VEEV : 226.00 (+1.80%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 123.88 (-3.72%)
PTCT : 30.98 (-3.04%)
Got $3,000? 3 Growth Stocks to Double Up On Right Now

There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important.

SRPT : 123.88 (-3.72%)
UBER : 81.30 (+0.33%)
SYM : 41.47 (+1.32%)
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?

It's always tough to be compared to a giant.

SRPT : 123.88 (-3.72%)
VRTX : 424.03 (-2.02%)
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today

One pundit feels there is solid potential in one of the company's more recently approved drugs.

JPM : 186.68 (+0.75%)
SRPT : 123.88 (-3.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 132.62
2nd Resistance Point 130.65
1st Resistance Point 127.26
Last Price 123.88
1st Support Level 121.90
2nd Support Level 119.93
3rd Support Level 116.54

See More

52-Week High 159.89
Last Price 123.88
Fibonacci 61.8% 119.92
Fibonacci 50% 107.57
Fibonacci 38.2% 95.22
52-Week Low 55.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar